Active	Status	Sponsor type	Region	Phase	Filter
14 Active 8 Inactive 22 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   - « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   Show only changed items Enrollment:

Advanced Filters

8 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Patterson, Thomas L
STOMP, NCT05534984: Study of Tecovirimat for Human Mpox Virus	Active, not recruiting	3	719	Japan, US, RoW	Tecovirimat Oral Capsule, Placebo, Tecovirimat Oral Capsule (Open Label)	National Institute of Allergy and Infectious Diseases (NIAID), SIGA Technologies	MPOX	10/24	09/25
OASIS, NCT05101187: Olorofim Aspergillus Infection Study	Recruiting	3	225	Europe, Canada, Japan, US, RoW	Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B)	F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi	Invasive Aspergillosis	09/25	11/26
FORMULA-OLS, NCT03583164 / 2017-001290-17: Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options	Completed	2	203	Europe, US, RoW	Olorofim, F901318	F2G Biotech GmbH, Iqvia Pty Ltd	Invasive Fungal Infections	02/23	02/23
Vigil, Karen J
STOMP, NCT05534984: Study of Tecovirimat for Human Mpox Virus	Active, not recruiting	3	719	Japan, US, RoW	Tecovirimat Oral Capsule, Placebo, Tecovirimat Oral Capsule (Open Label)	National Institute of Allergy and Infectious Diseases (NIAID), SIGA Technologies	MPOX	10/24	09/25
PROMISE-US, NCT05388474: A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab	Recruiting	N/A	200	US	No ibalizumab or Pre-ibalizumab treatment, Ibalizumab, On ibalizumab treatment	Theratechnologies, Excelsus Statistics Inc., Health Psychology Research Group (HPR), ICON Clinical Research	HIV Infections, Multi-Antiviral Resistance	12/25	06/26
Kitchell, Ellen
STOMP, NCT05534984: Study of Tecovirimat for Human Mpox Virus	Active, not recruiting	3	719	Japan, US, RoW	Tecovirimat Oral Capsule, Placebo, Tecovirimat Oral Capsule (Open Label)	National Institute of Allergy and Infectious Diseases (NIAID), SIGA Technologies	MPOX	10/24	09/25
Bender-Ignacio, Rachel
STOMP, NCT05534984: Study of Tecovirimat for Human Mpox Virus	Active, not recruiting	3	719	Japan, US, RoW	Tecovirimat Oral Capsule, Placebo, Tecovirimat Oral Capsule (Open Label)	National Institute of Allergy and Infectious Diseases (NIAID), SIGA Technologies	MPOX	10/24	09/25
NCT06694805: A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1	Recruiting	3	332	Europe, US	CAB LA + RPV LA, Oral ART	ViiV Healthcare	HIV Infections	05/26	12/27

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Patterson, Thomas L
STOMP, NCT05534984: Study of Tecovirimat for Human Mpox Virus	Active, not recruiting	3	719	Japan, US, RoW	Tecovirimat Oral Capsule, Placebo, Tecovirimat Oral Capsule (Open Label)	National Institute of Allergy and Infectious Diseases (NIAID), SIGA Technologies	MPOX	10/24	09/25
OASIS, NCT05101187: Olorofim Aspergillus Infection Study	Recruiting	3	225	Europe, Canada, Japan, US, RoW	Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B)	F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi	Invasive Aspergillosis	09/25	11/26
FORMULA-OLS, NCT03583164 / 2017-001290-17: Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options	Completed	2	203	Europe, US, RoW	Olorofim, F901318	F2G Biotech GmbH, Iqvia Pty Ltd	Invasive Fungal Infections	02/23	02/23
Vigil, Karen J
STOMP, NCT05534984: Study of Tecovirimat for Human Mpox Virus	Active, not recruiting	3	719	Japan, US, RoW	Tecovirimat Oral Capsule, Placebo, Tecovirimat Oral Capsule (Open Label)	National Institute of Allergy and Infectious Diseases (NIAID), SIGA Technologies	MPOX	10/24	09/25
PROMISE-US, NCT05388474: A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab	Recruiting	N/A	200	US	No ibalizumab or Pre-ibalizumab treatment, Ibalizumab, On ibalizumab treatment	Theratechnologies, Excelsus Statistics Inc., Health Psychology Research Group (HPR), ICON Clinical Research	HIV Infections, Multi-Antiviral Resistance	12/25	06/26
Kitchell, Ellen
STOMP, NCT05534984: Study of Tecovirimat for Human Mpox Virus	Active, not recruiting	3	719	Japan, US, RoW	Tecovirimat Oral Capsule, Placebo, Tecovirimat Oral Capsule (Open Label)	National Institute of Allergy and Infectious Diseases (NIAID), SIGA Technologies	MPOX	10/24	09/25
Bender-Ignacio, Rachel
STOMP, NCT05534984: Study of Tecovirimat for Human Mpox Virus	Active, not recruiting	3	719	Japan, US, RoW	Tecovirimat Oral Capsule, Placebo, Tecovirimat Oral Capsule (Open Label)	National Institute of Allergy and Infectious Diseases (NIAID), SIGA Technologies	MPOX	10/24	09/25
NCT06694805: A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1	Recruiting	3	332	Europe, US	CAB LA + RPV LA, Oral ART	ViiV Healthcare	HIV Infections	05/26	12/27